
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc. is focused on creating advanced allogeneic gamma delta T cell therapies, with significant progress seen in their lead candidate, prulacabtagene leucel (prula-cel), which has demonstrated promising efficacy in early Phase 1 trials for lupus nephritis (LN) and systemic lupus erythematosus (SLE). The company is also set to initiate a Phase 1 study for its next-generation candidate, ADI-212, targeting metastatic castration-resistant prostate cancer by mid-2026, with the potential for valuable data to emerge later that year. By leveraging third-party manufacturers for commercial-scale production, Adicet aims to minimize manufacturing risks, positioning itself favorably for upcoming advancements and potential market expansions, thus indicating a positive outlook for its stock.
Bears say
Adicet Bio Inc faces significant challenges that contribute to a negative financial outlook, including projected losses of $11.58 per share by 2026 and increased risks related to clinical efficacy and market competition. The company is grappling with the possibility of negative clinical data and slower development timelines, which could hinder its ability to secure regulatory approvals and achieve projected commercial success. Furthermore, with the lack of FDA approval for Vδ1 gamma-delta T-cell therapies and a reduced probability of clinical success for its lead candidate ADI-001, the potential for long-term dilution and decreased market share raises concerns about its financial viability.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares